Control Strategy in Pharma: How You Keep CQAs Under Control Batch After Batch
Definition
Control Strategy is the planned set of controls (technical and procedural) that ensures a pharmaceutical product is consistently manufactured to meet its Critical Quality Attributes (CQAs). A control strategy is built from process and product understanding and typically includes control of materials, process parameters, in-process tests, equipment settings, monitoring systems, and release testing. In simple terms: it is the “how we prevent failure” plan that converts development knowledge into routine GMP control.
Why Control Strategy Matters
Validation proves a process can work. A control strategy proves it will keep working in routine production. It matters because it:
- Prevents variability from turning into deviations, OOS, or batch failures
- Defines what must be monitored and what limits must be respected
- Justifies validation acceptance criteria and ongoing monitoring plans
- Creates a defendable rationale in regulatory submissions and inspections
- Supports lifecycle management and continuous improvement
Auditors often judge process maturity based on how clear and risk-based your control strategy is.
Control Strategy vs Control Plan vs Monitoring (Quick Clarity)
- Control Strategy: the overall concept and justification of controls derived from risk and understanding.
- Control Plan: the operational translation—who checks
These work together. A weak control strategy usually leads to reactive firefighting, not prevention.
What a Control Strategy Typically Includes
A robust control strategy spans the full lifecycle and usually covers:
- Material controls: supplier qualification, incoming testing, attribute limits (e.g., moisture, particle size)
- Process parameter controls: setpoints, ranges, alarms, and interlocks for CPPs
- Equipment controls: calibration, maintenance, qualified status, automation safeguards
- In-process controls (IPC): sampling, test methods, frequencies, and acceptance limits
- Environmental controls: cleanroom class, differential pressure, temperature/humidity, microbial monitoring (as applicable)
- Packaging and labeling controls: reconciliation, vision checks, line clearance, barcode verification
- Release testing: final product tests and specifications for CQAs
- Data integrity controls: audit trails, access control, record review and retention (where relevant)
How Control Strategy Links CQAs and CPPs
Control strategy is built on a simple logic chain:
- Define product intent (QTPP) and identify CQAs
- Identify parameters and material attributes that can impact CQAs
- Assess criticality (risk) to identify CPPs and high-impact material attributes
- Define controls that prevent or detect drift before CQAs fail
This is why control strategy is often described as “risk-based.” You control what matters most.
Key Building Blocks of an Audit-Ready Control Strategy
1) Proven Acceptable Ranges (PAR) and Operating Ranges
Control strategies often include operating ranges for CPPs that are justified by development/DOE data and validated evidence. These ranges are not arbitrary—they represent where performance is reliably acceptable.
2) Alert and Action Limits
Many processes use two levels of limits:
- Alert limits: early warning signals; investigation/trending triggers before failure occurs.
- Action limits: require immediate action, correction, and likely deviation handling.
Using only “spec limits” often leads to late detection. Alert/action limits improve prevention.
3) In-Process Controls (IPC) and Sampling Strategy
IPC controls include:
- What to sample (blend, granules, tablets, fill volume, seal integrity, etc.)
- Where to sample (locations that represent worst-case or highest risk)
- How often to sample (frequency justified by risk and variability)
- Acceptance criteria (clear pass/fail limits)
4) Automation Controls and Fail-Safes
For automated systems, control strategy often relies on:
- Alarms and interlocks that prevent unacceptable operation
- Recipe management and locked setpoints
- Role-based access controls for critical changes
- Audit trail and electronic record controls (if applicable)
5) Process Analytical Technology (PAT) Where Appropriate
PAT tools (like NIR for moisture or blend uniformity proxies) can shift control from end-product testing to real-time monitoring. PAT is not mandatory everywhere, but where used, it can strengthen process control significantly.
6) Control of Raw Materials and Supplier Variability
Material variability can break otherwise strong processes. Control strategy may include tighter material attribute limits, supplier agreements, testing frequency adjustments, or material classification based on risk.
7) Lifecycle Monitoring and CPV Linkage
Control strategy must not stop after PPQ. It should define how performance will be monitored (trending of CPPs/CQAs, deviation patterns, yield drift, IPC capability). This is where CPV and periodic review align strongly with control strategy.
Mini Example: Control Strategy for Tablet Compression
A tablet compression control strategy might include:
- CPP controls: compression force range, turret speed limits, feeder settings
- IPC tests: tablet weight, hardness, thickness, friability checks at defined intervals
- Alarm/interlock: automatic stop if weight deviates beyond action limit
- Material control: granule moisture range and particle size limits
- Monitoring: trending of weight adjustments and rejects to detect drift
This converts process understanding into daily operational control.
Common Mistakes (Audit Traps)
- Control strategy not linked to risk: controls selected without explaining why they matter.
- Too much reliance on end-product testing: catching failures late instead of preventing them.
- Limits not justified: setpoints and ranges chosen without data or rationale.
- Weak sampling logic: sampling locations/frequency not aligned with risk or variability.
- Ignoring materials: assuming raw material variability won’t affect CQAs.
- No lifecycle follow-through: controls defined but not monitored and trended after validation.
Audit-Ready Talking Points
- Control strategy is derived from process understanding and risk assessment linking CQAs and CPPs
- Controls include material, process, equipment, IPC, and data integrity elements as appropriate
- Limits (ranges, alert/action thresholds) are justified by development and validation evidence
- Automation safeguards and procedural controls prevent and detect drift early
- Control strategy is supported by lifecycle monitoring and continuous improvement
FAQs
What is a control strategy in pharma?
It is the planned set of controls that ensures the product consistently meets CQAs by controlling critical materials, process parameters, and monitoring/testing activities.
Is control strategy part of validation?
Yes. Validation activities provide evidence that the control strategy and defined ranges can deliver consistent quality, and ongoing monitoring confirms it remains effective.
What is the difference between IPC and control strategy?
IPC is one component (in-process testing). Control strategy is broader and includes material controls, equipment controls, process limits, alarms, sampling, and monitoring programs.
Do you need PAT for a control strategy?
No. PAT can strengthen control where suitable, but control strategy can also be robust using validated IPC tests, parameter control, and effective monitoring.
What is the most common control strategy audit issue?
Controls and limits that are not scientifically justified or not linked clearly to risks and CQAs, leading to reactive rather than preventive quality control.